Moorfields Eye Hospital to close its specials manufacturing facility | News in brief | Pharmaceutical Journal

: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our

Genetic testing is appropriate in certain situations, but for healthy people as a way to predict disease, it is imprecise and comes with a number of risks.

 

Moorfields Eye Hospital NHS Foundation Trust has decided to close its specials manufacturing facility in London, its board announced on 27 January 2015.

 

Manufacturing of specials has been suspended at the plant since December 2013 following concerns raised by the UK Medicines and Healthcare products Regulatory Agency (MHRA) about some of its practices and processes.

 

Manufacturing of specials has been suspended at the plant since December 2013 following concerns raised by the UK Medicines and Healthcare products Regulatory Agency (MHRA) about some of its practices and processes.

 

Since then Moorfields Pharmaceuticals has outsourced its specials production and the board has now decided that it would be uneconomic to return production to the site. The market for specials has shrunk – down by 28.6% since 2011 – at the same time that regulatory standards have become more rigorous, it says. Forty three staff are facing redundancy.

 

The company will continue its range of licensed medicines as well as its range of outsourced ophthalmic specials, which are not available from other suppliers.

 

Curated from Moorfields Eye Hospital to close its specials manufacturing facility | News in brief | Pharmaceutical Journal